New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
07:24 EDTECYTEndocyte shares can advance even if NSLC treatment fails, says RBC Capital
RBC Capital is upbeat on Endocyte's pipeline and believes that the company's long-term fundamentals have improved. The firm thinks the stock's risk/reward ratio is positive at current levels and keeps an Outperform rating on the shares.
News For ECYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
10:02 EDTECYTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:28 EDTECYTEndocyte downgraded to Hold from Buy at Brean Capital
Brean Capital downgraded Endocyte to Hold saying it views the company's data for vintafolide as "marginal."
September 29, 2014
06:27 EDTECYTEndocyte to host conference call
Subscribe for More Information
September 28, 2014
14:12 EDTECYTEndocyte says Phase 2b TARGET trial results show improved survival
Endocyte announced that the small molecule drug conjugate, SMDC, vintafolide in combination with docetaxel extended overall survival for patients with folate receptor positive recurrent non-small cell lung cancer, NSCLC, compared to patients receiving monotherapy docetaxel in its TARGET Phase 2b clinical trial. The late-breaking TARGET trial data will be presented today at the European Society for Medical Oncology Congress, ESMO, by Rohit Lal, M.D., consultant medical oncologist at Guys and St Thomas' Hospital and an Honorary Consultant Medical Oncologist for Kings College Hospital, London.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use